<DOC>
	<DOCNO>NCT00387270</DOCNO>
	<brief_summary>This study conduct determine safety tolerability Dimebon people Huntington 's disease short-term exposure ( one week ) long exposure ( three month ) . Also , study ass whether effect Dimebon symptoms Huntington 's disease , include cognitive ( think ability ) , motor ( movement ) , behavior , overall functioning .</brief_summary>
	<brief_title>Safety Study Novel Drug Dimebon Treat Patients With Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Clinical feature Huntington 's disease confirmatory family history HD , CAG repeat expansion great equal 36 Stage I , II , III HD total functional capacity great equal 5 Unified Huntington 's Disease Rating Scale Clinical evidence unstable medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Huntington 's disease</keyword>
	<keyword>Dimebon</keyword>
	<keyword>dose-escalation</keyword>
	<keyword>Phase 1-2a</keyword>
	<keyword>randomize</keyword>
	<keyword>control</keyword>
	<keyword>double-blind</keyword>
	<keyword>Unified Huntington 's Disease Rating Scale</keyword>
</DOC>